Lipidomics of Bioactive Lipids in Alzheimer’s and Parkinson’s Diseases: Where Are We?
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Lipids are not only constituents of cellular membranes, but they are also key signaling mediators, thus acting as “bioactive lipids”. Among the prominent roles exerted by bioactive lipids are immune regulation, inflammation, and maintenance of homeostasis. Accumulated evidence indicates the existence of a bidirectional relationship between the immune and nervous systems, and lipids can interact particularly with the aggregation and propagation of many pathogenic proteins that are well-renowned hallmarks of several neurodegenerative disorders, including Alzheimer’s (AD) and Parkinson’s (PD) diseases. In this review, we summarize the current knowledge about the presence and quantification of the main classes of endogenous bioactive lipids, namely glycerophospholipids/sphingolipids, classical eicosanoids, pro-resolving lipid mediators, and endocannabinoids, in AD and PD patients, as well as their most-used animal models, by means of lipidomic analyses, advocating for these lipid mediators as powerful biomarkers of pathology, diagnosis, and progression, as well as predictors of response or activity to different current therapies for these neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041 · cited 1×
“They all act as immunoresolvents; that is, they stimulate the cardinal signs of the resolution of inflammation: removal, relief, restoration, regeneration, and remission [3,7,8].”
BackgroundMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859 · cited 1×
“One of the neuropathophysiological hallmarks of PD is characterized by the accumulation of α-synuclein (α-syn) and the formation of filamentous aggregates called “Lewy bodies” in the brainstem, limbic system, and cortical areas, leading to a progressive loss of dopaminergic neurons in the substantia nigra and striatum…”
BackgroundEndocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation
Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, M. C. G., Ward, A. M., Hahn, Y. K., Lichtman, A. H., Conti, B., et al. (2011) · Science · doi:10.1126/science.1209200 · Cited by 727
Han, X., M. Holtzman, D., W. McKeel, D., Kelley, J., & Morris, J. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00997.x · Cited by 626 · cited 1×
“observed an enhancement of ceramide in the early AD stages in brain tissue lipid extracts by electrospray ionization mass spectrometry, while its concentration reduced with disease severity [22].”
BackgroundDeregulation of sphingolipid metabolism in Alzheimer’s disease
He, X., Huang, Y., Li, B., Gong, C.-X., & Schuchman, E. H. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.010 · Cited by 516
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485 · cited 2×
“As a matter of fact, many studies using cell culture and transgenic animals have investigated the potential mechanisms by which ApoE4 is implicated in the pathogenesis of Alzheimer’s disease, including studies that investigated alterations in lipid metabolism, causing the inhibition of neurite extension [10].”
BackgroundTrushina, E., Dutta, T., Persson, X.-M. T., Mielke, M. M., & Petersen, R. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063644 · Cited by 438 · cited 12×
“17- HDHA and 15-HETE UPLC-ToF-MS Acquity UPLC system (Waters, Milford) Human CSF Increased levels in AD patients compared to MCI [39]”
BackgroundMethodInfluentialBioactive Lipids and Chronic Inflammation: Managing the Fire Within
Chiurchiù, V., Leuti, A., & Maccarrone, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00038 · Cited by 427
Self-citationYeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein
Willingham, S., Outeiro, T. F., DeVit, M. J., Lindquist, S. L., & Muchowski, P. J. (2003) · Science · doi:10.1126/science.1090389 · Cited by 422
Snowden, S. G., Ebshiana, A. A., Hye, A., An, Y., Pletnikova, O., O’Brien, R., Troncoso, J., Legido-Quigley, C., & Thambisetty, M. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002266 · Cited by 309 · cited 2×
“In brain regions vulnerable to AD pathology—the middle frontal and inferior temporal gyri, there were decrements in LA, ALA, and AA, and increases in DHA [32].”
BackgroundMethodResolution of inflammation is altered in Alzheimer's disease
Wang, X., Zhu, M., Hjorth, E., Cortés‐Toro, V., Eyjolfsdottir, H., Graff, C., Nennesmo, I., Palmblad, J., Eriksdotter, M., Sambamurti, K., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.024 · Cited by 301 · cited 2×
“This study found a reduction of RvD1 in CSF but not in the hippocampus, and it found decreased levels of MaR1 in the hippocampus in post-mortem human AD brains [47].”
BackgroundMethodGBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
Riboldi, G. M., & Di Fonzo, A. B. (2019) · Cells · doi:10.3390/cells8040364 · Cited by 274
Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases
Filippov, V., Song, M. A., Zhang, K., Vinters, H. V., Tung, S., Kirsch, W. M., Yang, J., & Duerksen-Hughes, P. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111202 · Cited by 264 · cited 2×
“Bioactive Lipid Methods of Detection/Instruments Tissue Variation References SMs and ceramides ES/MS/MS Sciex API 3000 triple stage quadrupole tandem mass spectrometer Human brain SMs decreased and ceramide increased in brain regions of AD patients with extensive Aβ SMs increased and ceramide decreased in brain region…”
BackgroundZhao, Y., Calon, F., Julien, C., Winkler, J. W., Petasis, N. A., Lukiw, W. J., & Bazan, N. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015816 · Cited by 243 · cited 2×
“After this study, the reduction of NPD1 levels during the AD course have been corroborated in the hippocampus of the 3xTg mouse model of AD [46].”
MethodResultPiro, J. R., Benjamin, D. I., Duerr, J. M., Pi, Y., Gonzales, C., Wood, K. M., Schwartz, J. W., Nomura, D. K., & Samad, T. A. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.05.001 · Cited by 223
Astarita, G., Jung, K.-M., Berchtold, N. C., Nguyen, V. Q., Gillen, D. L., Head, E., Cotman, C. W., & Piomelli, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012538 · Cited by 218 · cited 2×
“AD patients have decreased DHA levels throughout their brains, including the disease-resistant regions, but the most prominent reduction occurs in the hippocampus, and DHA content has been found to show a positive correlation with dementia [33].”
BackgroundMethodPro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis
Zhu, M., Wang, X., Hjorth, E., Colas, R. A., Schroeder, L., Granholm, A.-C., Serhan, C. N., & Schultzberg, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9544-0 · Cited by 204 · cited 2×
“PD1, MaR1, and RvD5 LC-MS/MS LC-20AD HPLC and a SIL-20AC auto-injector paired with a Qtrap 6500 Entorhinal cortex of AD patients Decreased in AD patients compared to controls [48]”
BackgroundResultKrashia, P., Cordella, A., Nobili, A., La Barbera, L., Federici, M., Leuti, A., Campanelli, F., Natale, G., Marino, G., Calabrese, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11928-w · Cited by 188
Self-citationHertel, J., Harms, A. C., Heinken, A., Baldini, F., Thinnes, C. C., Glaab, E., Vasco, D. A., Pietzner, M., Stewart, I. D., Wareham, N. J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.035 · Cited by 162
Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging
Kröger, E., Verreault, R., Carmichael, P.-H., Lindsay, J., Julien, P., Dewailly, É., Ayotte, P., & Laurin, D. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26987 · Cited by 149 · cited 1×
“However, some studies reported no significant changes in DHA levels between erythrocytes or the brain tissue of AD and control subjects [68,69].”
BackgroundKantarci, A., Aytan, N., Palaska, I., Stephens, D., Crabtree, L., Benincasa, C., Jenkins, B. G., Carreras, I., & Dedeoglu, A. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.11.005 · Cited by 118
Bioactive lipids as modulators of immunity, inflammation and emotions
Chiurchiù, V., & Maccarrone, M. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.06.005 · Cited by 64
Self-citationProteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity
McLaughlin, P., Zhou, Y., Ma, T., Liu, J., Zhang, W., Hong, J., Kovacs, M., & Zhang, J. (2006) · Glia · doi:10.1002/glia.20294 · Cited by 55
Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer’s disease brain
Dominguez, G., Maddelein, M.-L., Pucelle, M., Nicaise, Y., Maurage, C.-A., Duyckaerts, C., Cuvillier, O., & Delisle, M.-B. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0527-z · Cited by 43
Cited by
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“These aspects have been reviewed in detail recently.(443,444) Role of neuroinflammation in neurodegeneration development Zhang et al.”
BackgroundGupta, R., Kumari, S., Senapati, A., Ambasta, R. K., & Kumar, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102013 · Cited by 134
Tong, B., Ba, Y., Li, Z., Yang, C., Su, K., Qi, H., Zhang, D., Liu, X., Wu, Y., Chen, Y., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106505 · Cited by 117
“In addition, there is increasing evidence that the lipidomic markers are increasingly supporting the diagnosis, prognosis, and detection of therapeutic effects of AD and PD (Chiurchiù et al., 2022).”
BackgroundDing, H., Reiss, A. B., Pinkhasov, A., & Kasselman, L. J. (2022) · Medicina · doi:10.3390/medicina58081025 · Cited by 32
“Inflammation and oxidative stress may result in synaptic and neuronal loss via mechanisms independent of amyloid formation [16,17].”
BackgroundLi, H., Zhao, Z., Zhu, L., Tan, Y., Zhang, Z., Zhang, Z., Kang, J., Lu, H., Peng, W., & Wu, Q. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.044 · Cited by 3
Metadata
- Authors
- Chiurchiù, V., Tiberi, M., Matteocci, A., Fazio, F., Siffeti, H., Saracini, S., Mercuri, N. B., & Sancesario, G.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-06-02
- Volume
- 23
- Issue
- 11
- Pages
- 6235
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4281913335
- Cited by
- 64
- References
- 25
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.